In vitro selection of glycopeptide-resistant variants of Enterococci

Puntorieri, M.; Cafiso, Viviana; Santagati, Maria; Messina, Calogero; Azzarelli, Cinzia; Catalano, Valentina; Bonfiglio, Giovanni; Giuseppe, Nicoletti; Stefani, Stefania

doi:10.1016/s0924-8579(99)00082-5

Search citation statements

Order By: Relevance

Paper Sections

Select...

In Vitro Activity Of Linezolid Compared With 12 Antimicrobia1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2002

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Europe, vancomycin‐resistant enterococci have a smaller impact than in the USA [1–10]. The extensive use of glycopeptides is responsible for their emergence, but differences in the prevalence of resistant strains noted in various countries cannot be explained so easily [12,13].…”

Section: In Vitro Activity Of Linezolid Compared With 12 Antimicrobiamentioning

confidence: 99%

Comparative activity of linezolid against staphylococci and enterococci isolated in Italy

Stefani

Mezzatesta

Tempera

et al. 2002

Clinical Microbiology and Infection

View full text Add to dashboard Cite

The activity of linezolid, a new oxazolidinone, was tested against 862 Gram-positive cocci isolated in Italy and compared with the activities of 12 antibiotics. Overall, MIC90s for linezolid (2-4 mg/L) indicated an in vitro activity comparable to that of vancomycin in methicillin-resistant Staphylococcus aureus (4 mg/L), S. epidermidis (2 mg/L) and methicillin-susceptible strains. Enterococcus faecalis strains were susceptible to linezolid (MIC90 2-4 mg/L), glycopeptides and beta-lactams. In E. faecium, only glycopeptides (MIC90 2 mg/L) and linezolid (MIC90 2 mg/L) were active. Linezolid was the only drug active against two strains of Enterococcus showing a VanA phenotype. Owing to its antibacterial profile, linezolid represents a promising drug for the treatment of Gram-positive infections.

show abstract

Section: In Vitro Activity Of Linezolid Compared With 12 Antimicrobiamentioning

confidence: 99%